Scholar Rock Holding Corp SRRK
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Scholar Rock to Present at Upcoming Investor Conferences
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Scholar Rock Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Scholar Rock to Present at Upcoming Investor Conferences
Scholar Rock to Report Third Quarter 2026 Financial Results on November 10, 2026
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)
Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm
Trading Information
- Previous Close Price
- $44.54
- Day Range
- $43.29–45.20
- 52-Week Range
- $36.78–61.76
- Bid/Ask
- $44.90 / $45.56
- Shares Outstanding
- 122.00M
- Market Cap
- $5.50B
- Volume/Avg
- 130 / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 289
- Website
- https://www.scholarrock.com
Valuation
Metric | SRRK |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 32.59 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | SRRK |
|---|---|
Quick Ratio | 5.19 |
Current Ratio | 5.41 |
Interest Coverage | −29.62 |
Quick Ratio
SRRK
Profitability
Metric | SRRK |
|---|---|
Return on Assets (Normalized) | −72.18% |
Return on Equity (Normalized) | −140.89% |
Return on Invested Capital (Normalized) | −83.07% |
Return on Assets
SRRK
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|LJQJ$L | LOCK|>?%G | $135B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|tPfkD# | LOCK|$@cf | $99B | |||
| Moderna Inc MRNA | LOCK|H!c#zz | LOCK|S# | $84B | |||
| argenx SE ADR ARGX | LOCK|@jr>!h | LOCK|q< | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|@tqkYc | LOCK|mD@ | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|VysNNlF! | LOCK|SmVQ | $31B | |||
| Incyte Corp INCY | LOCK|T<y@&!P | LOCK|d&d | $24B | |||
| BioNTech SE ADR BNTX | LOCK|r%y!Z< | LOCK|#M> | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|%<N!$f? | LOCK|$!Nqf | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|Vy$^$? | LOCK|&T$ | $15B |